Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Ocular Therapeutix (OCUL) over the last 12 years, with Q4 2025 value amounting to $86.3 million.

  • Ocular Therapeutix's Non-cash Items rose 10750.78% to $86.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $86.3 million, marking a year-over-year increase of 10750.78%. This contributed to the annual value of $86.3 million for FY2025, which is 65538.56% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Non-cash Items of $86.3 million as of Q4 2025, which was up 10750.78% from $41.6 million recorded in Q4 2024.
  • Ocular Therapeutix's 5-year Non-cash Items high stood at $86.3 million for Q4 2025, and its period low was $7000.0 during Q4 2022.
  • Over the past 5 years, Ocular Therapeutix's median Non-cash Items value was $13.3 million (recorded in 2021), while the average stood at $28.9 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Non-cash Items crashed by 9994.73% in 2022, and later surged by 4795714.29% in 2023.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Non-cash Items stood at $13.3 million in 2021, then tumbled by 99.95% to $7000.0 in 2022, then surged by 47957.14% to $3.4 million in 2023, then surged by 1135.73% to $41.6 million in 2024, then surged by 107.51% to $86.3 million in 2025.
  • Its last three reported values are $86.3 million in Q4 2025, $41.6 million for Q4 2024, and $3.4 million during Q4 2023.